Skip to content

The Susatu PHOENIX Trial ‘SPOT’ - A prospective, single-center, interventional trial to determine the clinical performance of a novel osteosynthesis material detector in comparison to standard clinical care

The Susatu PHOENIX Trial ‘SPOT’ - A prospective, single-center, interventional trial to determine the clinical performance of a novel osteosynthesis material detector in comparison to standard clinical care - SPOT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00039037
Enrollment
10
Registered
2026-01-21
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z47.0

Interventions

Group 1: The course of the intervention in the clinical investigation will follow the standard procedure as routinely performed at the Investigational Site – basically without the use of an auxiliary

Sponsors

susatu GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Preceding treatment with osteosynthesis material in terms of free implanted screws • Indication for removal of the free implanted screws after fracture healing based on the assessment of the treating physician • Free implanted screw to be removed is located in the area of the foot/ankle joint or knee • Screw type and condition identifiable before the intervention Screw size and type covered by the intended use of the susatu PHOENIX Metal Detector • Patient has no implanted active medical devices • Patient has an age =18 years at time of consent • Patient is not pregnant or breastfeeding • Patient has no documented alcohol or drug abuse • Patient is not an employee of the Investigational Site, with direct involvement in this trial or other trials under the direction of the Investigational Site, as well as not a family member of the investigators • Patient is not a prisoner • Patient has been adequately informed of risks and requirements of the trial and written informed consent is provided • Patient was not participating in any other trial involving investigational drugs or devices within 4 weeks prior to screening and patient must agree not to participate in any other clinical trial at the same time and not for a period of 1 month after the SPOT Trial Delayed identifiable inclusion criterion: • Screw head not directly recognisable after standard surgical preparation due to overgrowth of bone material or connective tissue

Exclusion criteria

Exclusion criteria: • Patient is unwilling or unable to comply with trial requirements • Patients who met all inclusion criteria but had changes that affected at least one inclusion criterion before the procedure was performed.

Design outcomes

Primary

MeasureTime frame
Determination of the time duration ZEIT between the moment the surgeon picks up the susatu PHOENIX Metal Detector – following the completion of site preparation – and the successful detection of the screw head. (Evidence of the device’s clinical performance is obtained by comparing ZEIT with a predefined standard value.)

Countries

Switzerland

Contacts

Public ContactMichael Schär

Inselspital, Universitätsspital Bern Universitätsklinik für Orthopädische Chirurgie und Traumatologie

Michael.Schaer@insel.ch+41 31 632 21 11

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026